financetom
Business
financetom
/
Business
/
Lyft Sees Sequential Growth in Short-Term Bookings as First-Quarter Results Top Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lyft Sees Sequential Growth in Short-Term Bookings as First-Quarter Results Top Views
May 8, 2024 3:59 AM

06:19 AM EDT, 05/08/2024 (MT Newswires) -- Lyft's ( LYFT ) shares gained early Wednesday after delivering better-than-expected first-quarter results amid robust demand for its ride-hailing services, while the company forecast sequential bookings growth for the current three-month period.

Gross bookings, an important indicator of the scale and impact of the firm's overall platform, is set to come in between $4 billion and $4.1 billion for the second quarter, Lyft ( LYFT ) said late Tuesday. In the March quarter, the metric advanced 21% on an annual basis to $3.69 billion. The stock rose 5.4% in premarket activity.

"We continue to see strong demand for rideshare from drivers and from riders," Chief Financial Officer Erin Brewer said during a conference call, according to a Capital IQ transcript. "And as the weather has gotten better, we've seen more bike and scooter usage, which is additive to both rides and active riders on a sequential basis in (the second quarter)."

Adjusted earnings before interest, taxes, depreciation and amortization is expected to be in a range of $95 million to $100 million for the ongoing period. Adjusted EBITDA margin, which is calculated as a percentage of gross bookings, is forecast to be at roughly 2.4%.

The company reported adjusted earnings of $0.15 per share for the first quarter, up from $0.07 the year before, according to an investor presentation. The Street's view was for normalized EPS of $0.08. Revenue climbed 28% to $1.28 billion, topping analysts' $1.16 billion estimate.

Lyft's ( LYFT ) active riders inclined 12% to 21.9 million during the quarter, reflecting an improvement in rider retention as well as more new riders. Rides soared 23% to 187.7 million driven by robust rideshare demand. "Growth in early morning commute and weekend evening trips was particularly strong, which is a continuation of the trends we saw in the back half of 2023," Brewer said on the call.

"We had a great start to 2024 with very strong first quarter results," Chief Executive David Risher told analysts. "We are on track to deliver full-year goals with a higher level of free cash flow that we initially shared."

The company now anticipates at least 70% of adjusted EBITDA to convert to free cash flow for the 2024 year, compared with previous expectations for a roughly half conversion of the figure. The firm continues to project gross bookings to increase "slightly faster" than its mid-teens rides growth guidance.

Price: 17.65, Change: +1.05, Percent Change: +6.32

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UK's DS Smith in deal talks with International Paper
UK's DS Smith in deal talks with International Paper
Mar 26, 2024
March 26 (Reuters) - Paper and packaging company DS Smith ( DITHF ) said on Tuesday that it is in discussions with U.S.-listed International Paper ( IP ) regarding a proposal to buy the British packaging firm through a possible all-share offer. Under the terms of the proposal, DS Smith ( DITHF ) shareholders would receive 0.1285 shares in International...
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Mar 26, 2024
Monday, Biohaven’s CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company’s experimental obesity drug. Biohaven ( BHVN ) said it is developing an obesity drug that works differently from Novo Nordisk A/S’s and Eli Lilly And Co’s popular GLP-1 drugs. The experimental obesity drug, dubbed taldefgrobep alfa (BHVN-2000), could prevent muscle loss while helping shed weight. The company highlights that 20%-50%...
Spotify Technology Unusual Options Activity
Spotify Technology Unusual Options Activity
Mar 26, 2024
Investors with a lot of money to spend have taken a bullish stance on Spotify Technology ( SPOT ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Palisades Goldcorp Reports Renewal of Normal Course Issuer Bid
Palisades Goldcorp Reports Renewal of Normal Course Issuer Bid
Mar 26, 2024
01:46 PM EDT, 03/26/2024 (MT Newswires) -- Palisades Goldcorp Ltd. ( PLGDF ) on Tuesday rose 2.2% on last look after reporting that it has secured approval from the TSX Venture Exchange for the company's plan to renew its normal course issuer bid for common shares through the facilities of the TSX-V. Effective April 1, the renewal allows the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved